World Journal of Nuclear Medicine : 2012 - 11(3) http://www.wjnm.org/currentissue.asp World J Nucl Med 2012 - 11(3) World Journal of Nuclear Medicine Medknow Publications1450-1147 When was the Last Time You did Something for the First Time? Ajit Kumar Padhy Editorial World Journal of Nuclear Medicine 2012 11(3):99-100doi:10.4103/1450-1147.103404 World Journal of Nuclear Medicine 10.4103/1450-1147.103404 http://www.wjnm.org/text.asp?2012/11/3/99/103404 http://www.wjnm.org/text.asp?2012/11/3/99/103404113 99 100 http://www.wjnm.org/text.asp?2012/11/3/99/103404 Ajit Kumar Padhy

World Journal of Nuclear Medicine 2012 11(3):99-100

]]> Sat,10 Nov 2012http://www.wjnm.org/text.asp?2012/11/3/99/103404 Nuclear Medicine in Finland Kalevi Kairemo Editorial World Journal of Nuclear Medicine 2012 11(3):101-102doi:10.4103/1450-1147.103406 World Journal of Nuclear Medicine 10.4103/1450-1147.103406 http://www.wjnm.org/text.asp?2012/11/3/101/103406 http://www.wjnm.org/text.asp?2012/11/3/101/103406113 101 102 http://www.wjnm.org/text.asp?2012/11/3/101/103406 Kalevi Kairemo

World Journal of Nuclear Medicine 2012 11(3):101-102

]]> Sat,10 Nov 2012http://www.wjnm.org/text.asp?2012/11/3/101/103406 Global WARMTH for Patients with Cancer J Harvey Turner Editorial World Journal of Nuclear Medicine 2012 11(3):103-104doi:10.4103/1450-1147.103407 World Journal of Nuclear Medicine 10.4103/1450-1147.103407 http://www.wjnm.org/text.asp?2012/11/3/103/103407 http://www.wjnm.org/text.asp?2012/11/3/103/103407113 103 104 http://www.wjnm.org/text.asp?2012/11/3/103/103407 J Harvey Turner

World Journal of Nuclear Medicine 2012 11(3):103-104

]]> Sat,10 Nov 2012http://www.wjnm.org/text.asp?2012/11/3/103/103407 Standard Operating Procedure for In-house Preparation of 131 I-rituximab for Radioimmunotherapy of Non-Hodgkin's Lymphoma Matthew D Pickford J Harvey Turner Original Article World Journal of Nuclear Medicine 2012 11(3):105-109doi:10.4103/1450-1147.103408 World Journal of Nuclear Medicine 10.4103/1450-1147.103408 http://www.wjnm.org/text.asp?2012/11/3/105/103408 http://www.wjnm.org/text.asp?2012/11/3/105/103408113 105 109 http://www.wjnm.org/text.asp?2012/11/3/105/103408 Matthew D Pickford, J Harvey Turner

World Journal of Nuclear Medicine 2012 11(3):105-109

A Standard Operating Procedure (SOP) has been formulated for in-house preparation, quality control, dispensing and administration of 131 I-rituximab appropriate for the safe, effective, radioimmunotherapy of non-Hodgkin lymphoma. A decade of experience of semi-automated radioiodination of rituximab in our hospital radiopharmaceutical laboratory was analysed. The methodology was then refined for safe, practical, affordable application to radioimmunotherapy of lymphoma in departments of nuclear medicine in developing countries. This SOP has the potential to be incorporated into good laboratory practice conditions appropriate for local regulatory agency requirements.]]> Sat,10 Nov 2012http://www.wjnm.org/text.asp?2012/11/3/105/103408 Standard Operating Procedure for Prospective Individualised Dosimetry for [131] I-rituximab Radioimmunotherapy of Non-Hodgkin's Lymphoma Phillipe J Calais J Harvey Turner Original Article World Journal of Nuclear Medicine 2012 11(3):110-116doi:10.4103/1450-1147.103409 World Journal of Nuclear Medicine 10.4103/1450-1147.103409 http://www.wjnm.org/text.asp?2012/11/3/110/103409 http://www.wjnm.org/text.asp?2012/11/3/110/103409113 110 116 http://www.wjnm.org/text.asp?2012/11/3/110/103409 Phillipe J Calais, J Harvey Turner

World Journal of Nuclear Medicine 2012 11(3):110-116

Radioimmunotherapy (RIT) is an attractive therapy for non-Hodgkin's lymphoma (NHL) as it allows targeted tumor irradiation which provides a cytotoxic effect significantly greater than that of the immune-mediated effects of a non-radioactive, or 'cold', antibody alone. Anti-CD20 antibodies such as rituximab are ideal for RIT, as not only is it easily iodinated, but the CD20 antigen is found on more than 95% of B-cell NHL. A standard operating procedure (SOP) has been formulated for personalized prospective dosimetry for safe, effective outpatient 131 I-rituximab RIT of NHL. Over five years, experience of treatment of outpatients with 131 I-rituximab was analyzed with respect to critical organ radiation dose in patients and radiation exposure of their carers. This radiation safety methodology has been refined; and offers the potential for safe, practical application to outpatient 131 I-rituximab RIT of lymphoma in general and in developing countries in particular. Given endorsement and sanction of this SOP by local regulatory authorities the personalized dosimetry paradigm will facilitate incorporation of RIT into the routine clinical practice of therapeutic nuclear oncology worldwide.]]> Sat,10 Nov 2012http://www.wjnm.org/text.asp?2012/11/3/110/103409 Warmth 7th International Conference on Radiopharmaceutical Therapy (Icrt 2012) Levi, Finland Abstracts World Journal of Nuclear Medicine 2012 11(3):117-117World Journal of Nuclear Medicine http://www.wjnm.org/text.asp?2012/11/3/117/103411 http://www.wjnm.org/text.asp?2012/11/3/117/103411113 117 117 http://www.wjnm.org/text.asp?2012/11/3/117/103411

World Journal of Nuclear Medicine 2012 11(3):117-117

]]> Sat,10 Nov 2012http://www.wjnm.org/text.asp?2012/11/3/117/103411 Pre-conference Symposium on Nuclear Cardiology Abstracts World Journal of Nuclear Medicine 2012 11(3):118-121World Journal of Nuclear Medicine http://www.wjnm.org/text.asp?2012/11/3/118/103412 http://www.wjnm.org/text.asp?2012/11/3/118/103412113 118 121 http://www.wjnm.org/text.asp?2012/11/3/118/103412

World Journal of Nuclear Medicine 2012 11(3):118-121

]]> Sat,10 Nov 2012http://www.wjnm.org/text.asp?2012/11/3/118/103412 ICRT-Speakers' Abstracts Abstracts World Journal of Nuclear Medicine 2012 11(3):121-153World Journal of Nuclear Medicine http://www.wjnm.org/text.asp?2012/11/3/121/103414 http://www.wjnm.org/text.asp?2012/11/3/121/103414113 121 153 http://www.wjnm.org/text.asp?2012/11/3/121/103414

World Journal of Nuclear Medicine 2012 11(3):121-153

]]> Sat,10 Nov 2012http://www.wjnm.org/text.asp?2012/11/3/121/103414 ICRT-Abstracts of Oral Presentations Abstracts World Journal of Nuclear Medicine 2012 11(3):154-159World Journal of Nuclear Medicine http://www.wjnm.org/text.asp?2012/11/3/154/103415 http://www.wjnm.org/text.asp?2012/11/3/154/103415113 154 159 http://www.wjnm.org/text.asp?2012/11/3/154/103415

World Journal of Nuclear Medicine 2012 11(3):154-159

]]> Sat,10 Nov 2012http://www.wjnm.org/text.asp?2012/11/3/154/103415 ICRT-Abstracts of Poster Presentations Abstracts World Journal of Nuclear Medicine 2012 11(3):160-200World Journal of Nuclear Medicine http://www.wjnm.org/text.asp?2012/11/3/160/103416 http://www.wjnm.org/text.asp?2012/11/3/160/103416113 160 200 http://www.wjnm.org/text.asp?2012/11/3/160/103416

World Journal of Nuclear Medicine 2012 11(3):160-200

]]> Sat,10 Nov 2012http://www.wjnm.org/text.asp?2012/11/3/160/103416